-
Je něco špatně v tomto záznamu ?
Impaired human immunodeficiency virus type 1 replicative fitness in atypical viremic non-progressor individuals
J. Weber, RM. Gibson, L. Sácká, D. Strunin, J. Hodek, J. Weberová, M. Pávová, DJ. Alouani, R. Asaad, B. Rodriguez, MM. Lederman, ME. Quiñones-Mateu,
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články
NLK
BioMedCentral
od 2004-12-01
BioMedCentral Open Access
od 2004
Directory of Open Access Journals
od 2004
Free Medical Journals
od 2004
PubMed Central
od 2004
Europe PubMed Central
od 2004
ProQuest Central
od 2009-01-01
Open Access Digital Library
od 2004-12-01
Open Access Digital Library
od 2004-01-01
Open Access Digital Library
od 2004-01-01
Health & Medicine (ProQuest)
od 2009-01-01
Public Health Database (ProQuest)
od 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2004
Springer Nature OA/Free Journals
od 2004-12-01
- MeSH
- dlouhodobě přežívající nosiči HIV * MeSH
- dospělí MeSH
- genetická variace MeSH
- genetická zdatnost * MeSH
- genom virový MeSH
- HIV infekce virologie MeSH
- HIV-1 klasifikace genetika izolace a purifikace fyziologie MeSH
- kohortové studie MeSH
- lidé středního věku MeSH
- lidé MeSH
- replikace viru * MeSH
- sekvenční analýza DNA MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Progression rates from initial HIV-1 infection to advanced AIDS vary significantly among infected individuals. A distinct subgroup of HIV-1-infected individuals-termed viremic non-progressors (VNP) or controllers-do not seem to progress to AIDS, maintaining high CD4+T cell counts despite high levels of viremia for many years. Several studies have evaluated multiple host factors, including immune activation, trying to elucidate the atypical HIV-1 disease progression in these patients; however, limited work has been done to characterize viral factors in viremic controllers. METHODS: We analyzed HIV-1 isolates from three VNP individuals and compared the replicative fitness, near full-length HIV-1 genomes and intra-patient HIV-1 genetic diversity with viruses from three typical (TP) and one rapid (RP) progressor individuals. RESULTS: Viremic non-progressors and typical patients were infected for >10 years (range 10-17 years), with a mean CD4+T-cell count of 472 cells/mm3(442-529) and 400 cells/mm3(126-789), respectively. VNP individuals had a less marked decline in CD4+cells (mean -0.56, range -0.4 to -0.7 CD4+/month) than TP patients (mean -10.3, -8.2 to -13.1 CD4+/month). Interestingly, VNP individuals carried viruses with impaired replicative fitness, compared to HIV-1 isolates from the TP and RP patients (p < 0.05, 95% CI). Although analyses of the near full-length HIV-1 genomes showed no clear patterns of single-nucleotide polymorphisms (SNP) that could explain the decrease in replicative fitness, both the number of SNPs and HIV-1 population diversity correlated inversely with the replication capacity of the viruses (r = -0.956 andr = -0.878,p < 0.01, respectively). CONCLUSION: It is likely that complex multifactorial parameters govern HIV-1 disease progression in each individual, starting with the infecting virus (phenotype, load, and quasispecies diversity) and the intrinsic ability of the host to respond to the infection. Here we analyzed a subset of viremic controller patients and demonstrated that similar to the phenomenon observed in patients with a discordant response to antiretroviral therapy (i.e., high CD4+cell counts with detectable plasma HIV-1 RNA load), reduced viral replicative fitness seems to be linked to slow disease progression in these antiretroviral-naïve individuals.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18010733
- 003
- CZ-PrNML
- 005
- 20180419144247.0
- 007
- ta
- 008
- 180404s2017 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s12981-017-0144-0 $2 doi
- 035 __
- $a (PubMed)28331526
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Weber, Jan $u 0000 0001 1015 3316grid.418095.1Institute of Organic Chemistry and Biochemistry v.v.i., Academy of Sciences of the Czech Republic, Flemingovo n. 2, 166 10 Prague 6, Czech Republic.
- 245 10
- $a Impaired human immunodeficiency virus type 1 replicative fitness in atypical viremic non-progressor individuals / $c J. Weber, RM. Gibson, L. Sácká, D. Strunin, J. Hodek, J. Weberová, M. Pávová, DJ. Alouani, R. Asaad, B. Rodriguez, MM. Lederman, ME. Quiñones-Mateu,
- 520 9_
- $a BACKGROUND: Progression rates from initial HIV-1 infection to advanced AIDS vary significantly among infected individuals. A distinct subgroup of HIV-1-infected individuals-termed viremic non-progressors (VNP) or controllers-do not seem to progress to AIDS, maintaining high CD4+T cell counts despite high levels of viremia for many years. Several studies have evaluated multiple host factors, including immune activation, trying to elucidate the atypical HIV-1 disease progression in these patients; however, limited work has been done to characterize viral factors in viremic controllers. METHODS: We analyzed HIV-1 isolates from three VNP individuals and compared the replicative fitness, near full-length HIV-1 genomes and intra-patient HIV-1 genetic diversity with viruses from three typical (TP) and one rapid (RP) progressor individuals. RESULTS: Viremic non-progressors and typical patients were infected for >10 years (range 10-17 years), with a mean CD4+T-cell count of 472 cells/mm3(442-529) and 400 cells/mm3(126-789), respectively. VNP individuals had a less marked decline in CD4+cells (mean -0.56, range -0.4 to -0.7 CD4+/month) than TP patients (mean -10.3, -8.2 to -13.1 CD4+/month). Interestingly, VNP individuals carried viruses with impaired replicative fitness, compared to HIV-1 isolates from the TP and RP patients (p < 0.05, 95% CI). Although analyses of the near full-length HIV-1 genomes showed no clear patterns of single-nucleotide polymorphisms (SNP) that could explain the decrease in replicative fitness, both the number of SNPs and HIV-1 population diversity correlated inversely with the replication capacity of the viruses (r = -0.956 andr = -0.878,p < 0.01, respectively). CONCLUSION: It is likely that complex multifactorial parameters govern HIV-1 disease progression in each individual, starting with the infecting virus (phenotype, load, and quasispecies diversity) and the intrinsic ability of the host to respond to the infection. Here we analyzed a subset of viremic controller patients and demonstrated that similar to the phenomenon observed in patients with a discordant response to antiretroviral therapy (i.e., high CD4+cell counts with detectable plasma HIV-1 RNA load), reduced viral replicative fitness seems to be linked to slow disease progression in these antiretroviral-naïve individuals.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a kohortové studie $7 D015331
- 650 12
- $a genetická zdatnost $7 D056084
- 650 _2
- $a genetická variace $7 D014644
- 650 _2
- $a genom virový $7 D016679
- 650 _2
- $a HIV infekce $x virologie $7 D015658
- 650 12
- $a dlouhodobě přežívající nosiči HIV $7 D020276
- 650 _2
- $a HIV-1 $x klasifikace $x genetika $x izolace a purifikace $x fyziologie $7 D015497
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a sekvenční analýza DNA $7 D017422
- 650 12
- $a replikace viru $7 D014779
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Gibson, Richard M $u 0000 0000 9149 4843grid.443867.aUniversity Hospital Translational Laboratory, University Hospitals Cleveland Medical Center, Cleveland, OH USA.
- 700 1_
- $a Sácká, Lenka $u 0000 0001 1015 3316grid.418095.1Institute of Organic Chemistry and Biochemistry v.v.i., Academy of Sciences of the Czech Republic, Flemingovo n. 2, 166 10 Prague 6, Czech Republic.
- 700 1_
- $a Strunin, Dmytro $u 0000 0001 1015 3316grid.418095.1Institute of Organic Chemistry and Biochemistry v.v.i., Academy of Sciences of the Czech Republic, Flemingovo n. 2, 166 10 Prague 6, Czech Republic.
- 700 1_
- $a Hodek, Jan $u 0000 0001 1015 3316grid.418095.1Institute of Organic Chemistry and Biochemistry v.v.i., Academy of Sciences of the Czech Republic, Flemingovo n. 2, 166 10 Prague 6, Czech Republic.
- 700 1_
- $a Weberová, Jitka $u 0000 0001 1015 3316grid.418095.1Institute of Organic Chemistry and Biochemistry v.v.i., Academy of Sciences of the Czech Republic, Flemingovo n. 2, 166 10 Prague 6, Czech Republic.
- 700 1_
- $a Pávová, Marcela $u 0000 0001 1015 3316grid.418095.1Institute of Organic Chemistry and Biochemistry v.v.i., Academy of Sciences of the Czech Republic, Flemingovo n. 2, 166 10 Prague 6, Czech Republic.
- 700 1_
- $a Alouani, David J $u 0000 0000 9149 4843grid.443867.aUniversity Hospital Translational Laboratory, University Hospitals Cleveland Medical Center, Cleveland, OH USA.
- 700 1_
- $a Asaad, Robert $u 0000 0001 2164 3847grid.67105.35Department of Medicine, Case Western Reserve University/University Hospitals Cleveland Medical Center, 10900 Euclid Avenue, Cleveland, OH 44106-7288 USA.
- 700 1_
- $a Rodriguez, Benigno $u 0000 0001 2164 3847grid.67105.35Department of Medicine, Case Western Reserve University/University Hospitals Cleveland Medical Center, 10900 Euclid Avenue, Cleveland, OH 44106-7288 USA.
- 700 1_
- $a Lederman, Michael M $u 0000 0001 2164 3847grid.67105.35Department of Medicine, Case Western Reserve University/University Hospitals Cleveland Medical Center, 10900 Euclid Avenue, Cleveland, OH 44106-7288 USA.
- 700 1_
- $a Quiñones-Mateu, Miguel E $u 0000 0000 9149 4843grid.443867.aUniversity Hospital Translational Laboratory, University Hospitals Cleveland Medical Center, Cleveland, OH USA ; 0000 0001 2164 3847grid.67105.35Department of Medicine, Case Western Reserve University/University Hospitals Cleveland Medical Center, 10900 Euclid Avenue, Cleveland, OH 44106-7288 USA ; 0000 0001 2164 3847grid.67105.35Department of Pathology, Case Western Reserve University, Cleveland, OH USA.
- 773 0_
- $w MED00163149 $t AIDS research and therapy $x 1742-6405 $g Roč. 14, č. - (2017), s. 15
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28331526 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180404 $b ABA008
- 991 __
- $a 20180419144348 $b ABA008
- 999 __
- $a ok $b bmc $g 1288218 $s 1007545
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 14 $c - $d 15 $e 20170320 $i 1742-6405 $m AIDS research and therapy $n AIDS Res Ther $x MED00163149
- LZP __
- $a Pubmed-20180404